Company: PSTV
Filing Date: 2025-04-23
Form Type: S-3/A
Source: 0001193125-25-091456
Chunk: 16

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-04-23
Form: S-3/A
Chunk 16
---
 a price per share (or conversion or exercise price, as applicable) less than the exercise price of the Series A Common Stock Warrants then in effect, then the
exercise price of the Series A Common Stock Warrants will be reduced to such lower price, but no lower than the Floor Price, and the number of shares issuable upon exercise will be proportionately adjusted such that the aggregate exercise price
will remain unchanged.

Share Combination Event Adjustment. If at any time on or after the date of issuance there occurs any share split,
share dividend, share combination recapitalization or other similar transaction involving our common stock and the lowest daily volume weighted average price during the period commencing on the trading day immediately following the applicable date
of share combination event and ending on the fifth (5) trading day immediately following such date is less than the exercise price of the Warrants then in effect, then the exercise price of the
Warrants will be reduced to the lowest daily volume weighted average price during such period (subject to a minimum exercise price of the Floor Price), and the number of shares issuable upon exercise will be proportionately adjusted such that the
aggregate exercise price will remain unchanged.

6

Warrant Stockholder Approval. Under Nasdaq listing rules, the Warrants may not be
exercised unless and until we obtain the approval of our stockholders (the “Warrant Stockholder Approval”). While we intend to promptly seek stockholder approval, there is no guarantee that the Warrant Stockholder Approval will ever be
obtained. If we are unable to obtain the Warrant Stockholder Approval, the Warrants may not be exercised and will have substantially less value. In addition, we will incur substantial cost, and management will devote substantial time and attention,
in attempting to obtain the Warrant Stockholder Approval.

7

SELLING STOCKHOLDERS The selling stockholders listed in the table below may from time to time offer and sell up to an aggregate of 1,565,044,860 shares of common stock offered and issued in the March PIPE Financing pursuant to this prospectus and the applicable prospectus supplements, which consists of:

| • |     | up to 3,077,270 shares of common stock; |

| • |     | up to 19,650,000 shares of common stock issuable upon exercise of 
 Pre-Funded Warrants;                                              |

| • |     | up to 280,421,380 shares of common stock that could become issuable upon exercise of Series A Common Stock